

February 11, 2025

The Manager BSE Limited Corporate Relationship Department P. J. Towers, Dalal Street, Mumbai – 400 001. The Manager The National Stock Exchange of India Limited Exchange Plaza, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051.

BSE Scrip Code No. 524280

NSE Symbol: KOPRAN

Dear Sir/Madam,

Sub: Investor Presentation on Unaudited Financial Results for the quarter ended December 31, 2024.

Dear Sir / Madam,

Please find attached Investor Presentation on Unaudited Financial Results for the 3rd quarter ended December 31, 2024.

The above information will also be made available on the website of the Company <u>www.kopran.com</u>

Regards, For Kopran Limited

Sunil Sodhani Company Secretary & Compliance Officer Membership No. FCS3897 Encl.: a/a.





Pursuing Sustainable Growth

Exploring opportunities Safeguarding health





SAFE HARBOUR STATEMENT



This quarterly investor presentation has been prepared by Kopran Limited ('Kopran') and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied, should not be deemed to constitute an offer.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be 'forward-looking statements', including those relating to the general business plans and strategy of Kopran, its future financial condition and growth prospects, future developments in its industry and its competitive and regulatory environment, and statements which contain words or phrases such as 'will', 'expected to', 'horizons of growth', 'strong growth prospects', among many others, or similar expressions or variations of such expressions. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results, opportunities and growth potential to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to, risks with respect to API and Formulation businesses.

Kopran may alter, modify, or otherwise change in any manner, the content of this presentation, without obligation to notify any person of such revision or changes. This presentation cannot be copied and disseminated in any manner.



PERFORMANCE

- Financial Highlights
- Operational Performance
- API
- Formulation



PARTICULARS	Q-3 2024-25	Q-2 2024-25	Q-3 2023-24	9M 2024-25	9M 2023-24
Revenue from Operations	16,624	15,156	15,892	45,724	42,851
EBITDA*	2,291	1,474	2,358	5,581	5,272
Finance Costs	216	223	224	657	601
Depreciation	400	385	327	1,173	929
Tax Expenses	346	226	471	936	1,003
Net Profit	1,040	738	1,579	2,887	3,234
EBITDA Margin	13.78%	9.72%	14.84%	12.21%	12.30%

* EBIDTA excluding other income and forex losses


OPERATIONAL PERFORMANCE








APIS OPERATIONAL HIGHLIGHTS SEGMENT-WISE REVENUE MIX






APIS OPERATIONAL HIGHLIGHTS MARKET-WISE REVENUE MIX






Formulations OPERATIONAL HIGHLIGHTS REGION-WISE SALES BREAK-UP

Q3 FY 2024-25 (Rs. In Lakhs)




9M 2024-25 (Rs. In Lakhs)





Formulations OPERATIONAL HIGHLIGHTS PRODUCT-WISE REVENUE MIX





Company Overview

- About Us
- Business Overview API
- Business Overview Formulations
- Driving Sustainable Growth

KOPRAN LIMITED A GLOBAL PHARMACEUTICAL COMPANY



An integrated Pharmaceutical Company, committed to supplying International Quality Formulations and Active Pharmaceutical Ingredients (APIs) globally.

State-of-the-art manufacturing facilities and products with various accreditations and approvals by major global regulatory authorities.

The formulations vertical is operated through Kopran Limited.

The API vertical is being operated under Kopran Research Laboratories Ltd. (KRLL), a wholly owned subsidiary of Kopran Limited





* Our presence across two major verticals in the pharmaceutical value chain

BUSINESS OVERVIEW API



API VERTICAL

- Development, manufacturing and sale of diverse APIs and Advanced Intermediates
- One of the leaders in Atenolol
- One of the major players in Sterile Carbapenems
- World-class facility and quality systems
- ***** Catering export and domestic market

DEDICATED AND VERSATILE FACILITIES FOR

- Atenolol
- Cephalosporins Non-Sterile & Sterile
- Macrolides
- Granules
- * Sterile Carbapenems
- Multipurpose plants
- Pilot plants

PRODUCT SEGMENT

*	Anti-hypertensive
*	Macrolide
*	Neuromodulator
*	Urological
*	Anti-infective/Anti-acne
*	Sterile Carbapenem
*	Sterile Cephalosporin
*	Anti-thrombotic
*	Intermediate
*	Anti-Diabetic
*	Cardiology

- * NSAIDs
- Anti Lipid

FACILITY


Located at MIDC Mahad, Maharashtra

11,900 sq. mts. built-up area



BUSINESS OVERVIEW FORMULATIONS





FORMULATIONS VERTICAL

- Development and manufacturing of oral solid dosages and dry powder formulations for both Penicillin- and Non-Penicillin-based drugs
- Catering 100% export markets of both Regulated and Non-Regulated
- ✤ Manufacturers of more than 100 dosages meeting the standards of international markets which includes Tablets, Capsules, Dry Powder and Suspension

DEDICATED FACILITIES

- Penicillin-based finished oral dosage forms
- Non-Penicillin-based finished oral dosage forms



Located at Khopoli, Maharashtra

11,432 sq. mts. built-up area

DRIVING SUSTAINABLE GROWTH STRATEGIC IMPERATIVES



GROWTH AND SUSTAINABILITY

- Focus on R&D to develop niche, high-value/high-volume APIs and intermediates
- Capacity expansion
- Compliance with Global Regulatory standards
- Synergies between APIs and formulations
- Setting up API and R&D facility at Panoli

COST LEADERSHIP

- Development of intermediates for APIs
- Reducing dependence on China to move towards self sufficiency
- Optimising operational cost
- Process improvements: Improving yields of existing products
- Automisation of packing lines in formulations

BALANCE PROFITABILITY & INVESTMENT FOR FUTURE

- Prudent capital allocation
- Increase asset to turnover ratio

BUSINESS DEVELOPMENT

- Leveraging customer base for new products
- New customers and newer geographies
- New regulatory filings and registrations

DRIVING SUSTAINABLE GROWTH REGULATORY COMPLIANCE




OFFERING BEST-IN-CLASS QUALITY THROUGH STRICT COMPLIANCE

FORMULATIONS ACCREDITATIONS

The Company maintains highest global regulatory standards of manufacturing and quality at its all plants

Approved by 15 countries including MHRA (UK), SAPHRA South Africa (formerly MCC), MMA Malta (EU GMP), Health Canada (Canada), FDA Philippines, DAV Vietnam, FDA Thailand, TMDA Tanzania (formerly TFDA), NDA Uganda, PPB Kenya, EFDA Ethiopia, MCAZ Zimbabwe, MOH Oman, MOH Iraq, MOH Yemen







FINANCIAL PERFORMANCE





FINANCIAL HIGHLIGHTS SNAPSHOT






FINANCE COSTS (Rs. LAKHS)

& Forex Losses

EBITDA * (Rs. LAKHS) 8,739 7,441 4,696 5,180 5,581 2019-20 2020-21 2021-22 2022-23 2023-24 Dec-24





NET PROFIT/(LOSS) (Rs. LAKHS)



FINANCIAL HIGHLIGHTS BUILDING SHAREHOLDER VALUE YEAR ON YEAR







CONSOLIDATED FINANCIAL HIGHLIGHTS (Rs. Lakhs)



PARTICULARS	Dec-2024	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Equity Share Capital	4,825	4,821	4,821	4,821	4,325	4,325
Other Equity	46,058	44,303	39,104	37,796	20,178	14,643
Networth	50,883	49,125	43,925	42,617	24,503	18,968
Fixed Assets(net)	30,220	27,830	23,457	18,623	15,508	14,139
Borrowings	11,682	9,923	7,524	7,248	6,429	7,806
Sales/Other Income	45,876	62,920	55,405	48,813	50,980	36,013
EBIDTA	5,581	7,441	5,180	8,739	8,178	4,696
Finance Costs	657	859	608	512	624	891
Depreciation	1,173	1,289	1,271	1,110	1,019	958
Tax Expenses	936	1,659	376	2,075	2,173	726
Net Profit/(loss)	2,887	5,096	2,723	6,103	6,161	2,120
Earning per share(Rs.)	5.99	10.57	5.65	13.77	14.24	4.86

Note: EBITDA excluding other income & Forex Losses

GOVERNANCE BOARD OF DIRECTORS





MR. SURENDRA SOMANI EXECUTIVE VICE CHAIRMAN



MR. ADARSH RAJENDRA SOMANI DIRECTOR



MRS. MAMTA BIYANI INDEPENDENT DIRECTOR



MR. NARAYAN ATAL INDEPENDENT DIRECTOR



DR. SIDDHAN SUBRAMANIAN INDEPENDENT DIRECTOR



DR. SUNITA BANERJI INDEPENDENT DIRECTOR



MR. SUSHEEL SOMANI DIRECTOR



MR. VARUN SURENDRA SOMANI DIRECTOR



Kopran

ABOUT KOPRAN LIMITED:

Kopran Limited is an integrated Pharmaceutical Company, committed to manufacturing and supplying International Quality Formulations and APIs worldwide. Kopran's manufacturing facilities and products have accreditations across all the continents. Research & Development for New Products and Processes for both Formulations & APIs form the strategy of Kopran's growth.

REGISTERED OFFICE:

Parijat House, 1076, Dr. E. Moses Road, Worli, Mumbai – 400 018, Maharashtra (India) Corporate Identification No.: L24230MH1958PLC011078 For more information about us, please visit www.kopran.com or contact: Name: Sunil Sodhani Tel.: +91 8692991999 Email: sunil@kopran.com